<DOC>
	<DOCNO>NCT00237627</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth cancer cell , either kill cell stop dividing . Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving doxorubicin hydrochloride liposome together bortezomib may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose bortezomib give together doxorubicin hydrochloride liposome see well work treat patient refractory hematologic cancer malignant solid tumor metastatic breast cancer .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome Bortezomib Treating Patients With Refractory Hematologic Cancer Malignant Solid Tumor Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose bortezomib administer pegylated doxorubicin hydrochloride liposome patient refractory hematologic solid tumor malignancy . ( Phase I [ close accrual 10/15/2007 ] ) - Determine dose-limiting toxicity regimen patient . ( Phase I [ close accrual 10/15/2007 ] ) - Determine response rate patient metastatic breast cancer treat regimen . ( Phase II ) Secondary - Determine response patient hematologic solid tumor malignancy treat regimen . ( Phase I [ close accrual 10/15/2007 ] ) - Determine time disease progression patient metastatic breast cancer treat regimen . ( Phase II ) - Obtain evidence safety regimen patient metastatic breast cancer . ( Phase II ) OUTLINE : This phase I ( close accrual 10/15/2007 ) , dose-escalation study bortezomib follow phase II study . - Phase I ( close accrual 10/15/2007 ) : Patients receive bortezomib IV day 1 , 4 , 8 , 11 pegylated doxorubicin hydrochloride liposome IV 1 hour day 4 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . - Phase II : Patients receive bortezomib ( maximum tolerate dose determine phase I ) pegylated doxorubicin hydrochloride liposome phase I . After completion study therapy , patient follow 1 week . PROJECTED ACCRUAL : A total 72 patient accrued phase I portion study 40 phase II portion .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I ( close accrual 10/15/2007 ) Histologically cytologically confirm solid tumor hematologic malignancy , include , limited , follow : Breast cancer Ovarian cancer Myeloid lymphoid leukemia Hodgkin nonHodgkin lymphoma Multiple myeloma Measurable evaluable disease Must meet 1 follow criterion : Refractory least one prior conventional treatment regimen Not candidate conventional therapy No conventional therapy exist No clinically radiographically significant pleural pericardial effusion Patients ascites may eligible discretion investigator Previously treat central nervous system disease allow provide stable &gt; 3 month site measurable disease Not eligible high priority protocol Phase II Diagnosis breast cancer Metastatic disease Measurable disease RECIST criteria No symptomatic brain metastasis Patients treat brain metastasis stable &gt; 3 month require chronic steroid eligible Hormone receptor status specify PATIENT CHARACTERISTICS : Phase I ( close accrual 10/15/2007 ) Karnofsky performance status 60100 % Life expectancy ≥ 2 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception WBC ≥ 2,000/mm³ ANC ≥ 1,500/mm³ ( ≥ 1,000/mm³ patient marrow infiltration ) Platelet count ≥ 100,000/mm³ ( ≥ 50,000/mm³ patient marrow infiltration ) Hemoglobin ≥ 8 g/dL Creatinine ≤ 2.5 mg/dL OR creatinine clearance ≥ 30 mL/min AST ALT &lt; 2.5 time upper limit normal ( ULN ) Total bilirubin &lt; 1.2 time ULN Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) &lt; 1.5 time ULN Patients receive warfarin heparin therapy history thrombosis , embolism , indication must PT and/or aPTT within accept therapeutic range indication Patients history reaction liposomal drug formulation due liposome may eligible discretion investigator No known HIV seropositivity No known active hepatitis A , B , C viral infection No New York Heart Association class III IV congestive heart failure LVEF ≥ 45 % 2D ECHO MUGA No acute ischemia new conduction system abnormality EKG No conduction system abnormality ( e.g. , leave bundle branch block ) EKG would preclude ability detect new ischemic episodes No myocardial infarction within past 6 month No significant comorbidity , poorly control hypertension , diabetes mellitus , serious medical psychiatric illness , opinion investigator , might compromise aspect study No uncontrolled infection Patients may febrile episode 38.5°C felt due tumor fever possibility infection rule evaluation No prior hypersensitivity reaction pegylated doxorubicin hydrochloride liposome doxorubicin hydrochloride Patients history reaction liposomal drug formulation and/or liposome , oppose encapsulated agent , may exclude discretion investigator Phase II Female male Menopausal status specify Karnofsky performance status 70100 % Life expectancy ≥ 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 2.5 mg/dL ( ≤ 200 µmol/L ) AST ALT ≤ 2 time ULN Alkaline phosphatase ≤ 2 time ULN ( unless attribute tumor ) Bilirubin ≤ ULN Cardiac ejection fraction &gt; 50 % MUGA 2D ECHO No clinical evidence congestive heart failure No New York Heart Association class IIIV cardiac disease No myocardial infarction within past 6 month No uncontrolled angina No severe uncontrolled ventricular arrhythmia No evidence acute ischemia active conduction system abnormality EKG Any EKG abnormality screen must document investigator medically relevant No grade 2 peripheral neuropathy within past 14 day No significant comorbidity would impair compliance study therapy interpretation study result No history hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride component pegylated doxorubicin hydrochloride liposome No hypersensitivity bortezomib , boron , mannitol No serious medical psychiatric illness likely interfere participation study PRIOR CONCURRENT THERAPY : Phase I ( close accrual 10/15/2007 ) More 3 week since prior major surgery More 3 week since prior concurrent radiotherapy More 4 week since prior concurrent immunotherapy ( i.e. , interferon , interleukin , cytokinebased treatment ) More 3 week since prior concurrent participation another therapeutic clinical trial experimental drug More 3 week since prior concurrent chemotherapy No prior doxorubicin dose &gt; 400 mg/m² No concurrent antineoplastic therapy Phase II More 6 month since prior anthracyclines More 14 day since prior investigational drug No 300 mg/m² prior doxorubicin 540 mg/m² prior epirubicin No two prior chemotherapy regimens metastatic disease No concurrent antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
</DOC>